DRIVIN G ROWTH - Dr. Reddy's

CHART B
NCE Pipeline
Diabetes DRF NPPC DRF 2593 DRF 2725
Cancer DRF 3188 DRF 1644 DRF 1042
Pain Management DRF 4848
Metabolic Disorders DRF 4832 DRF 4158
Cardiovascular Restenosis
PRE-CLINICAL TRIALS CLINICAL TRIALS
LICENSING DRF-4158 TO
NOVARTIS
THE COMPANY LICENSED
DRF-4158 to Novartis Pharma AG in a
US$ 55 million deal, which includes upfront
and milestone payments. DRF-4158 is
a second-generation dual activator for the
potential treatment of Type II diabetes,
diabetic dyslipidaemia, hypertension and
obesity.
PHASE III CLINICAL TRIALS
OF DRF-2725
AS ORIGINALLY PLANNED, Novo
Nordisk commenced Phase III clinical trials
of DRF-2725(now called Ragaglitazar). In
October, Novartis Pharma AG informed
Novo Nordisk of its decision not to continue
the collaboration regarding
commercialisation of Ragaglitazar for North
America. Novo Nordisk continues the
development without Novartis. Licensed by
Phase1 Phase 2 Phase3
Dr Reddy’s to Novo Nordisk, Ragaglitazar is
a novel dual-acting insulin sensitiser for the
treatment of Type II diabetes.
The Company received milestone and upfront
payments of Rs. 344 million during
the year under review.
DR. REDDY’S CURRENT R&D
PIPELINE
CHART B GIVES the Company’s existing
pipeline for new chemical entities (NCEs).
The Company set up a lab in Atlanta in
the year 2000, dedicated to discovery and
design of novel therapeutics. The focus
therapies are diabetes, inflammation, lipid
metabolism, oncology and cardio-vascular
diseases. It has developed a technology
platform and a discovery approach based
upon the CMS pathway. A lead molecule in
restenosis is currently in the late pre-clinical
stage. Other molecules are in their early
pre-clinical stages.
DR. REDDY’S LABORATORIES LTD. | MANAGEMENT DISCUSSION AND ANALYSIS | ANNUAL REPORT 2001-2002
55